Cambridge, MA, United States
Cambridge, MA, United States

Time filter

Source Type

Patent
ARIAD Pharmaceuticals Inc. and Merck | Date: 2014-04-30

The instant invention provides a method of treating a cancer selected from the group consisting of non-small cell lung cancer and breast cancer with an mTOR inhibitor and an v62 3 integrin antagonist, wherein the mTOR inhibitor is ridaforolimus, everolimus, temsirolimus or a combination thereof.


Patent
ARIAD Pharmaceuticals Inc. | Date: 2014-08-26

This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.


Patent
ARIAD Pharmaceuticals Inc. | Date: 2014-06-04

This invention relates to compounds of the general formula:


Patent
ARIAD Pharmaceuticals Inc. | Date: 2014-08-06

The invention features pharmaceutical compositions for treating cancer using 3-(imidazole[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-(4-((4-methylpiperazin-1-yl)-methyl)-3-(trifluoromethyl)phenyl)benzamide.


Patent
ARIAD Pharmaceuticals Inc. | Date: 2014-03-13

This invention relates to compounds of the general formula (I): in which the variable groups are as identified herein, and to preparation and use of the compounds.


Patent
ARIAD Pharmaceuticals Inc. | Date: 2015-04-20

The invention features compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.


Patent
ARIAD Pharmaceuticals Inc. | Date: 2016-01-25

The invention features compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.


Patent
ARIAD Pharmaceuticals Inc. | Date: 2015-01-28

The invention features methods and compositions for the synthesis of multimerizing agents.


Patent
ARIAD Pharmaceuticals Inc. | Date: 2016-01-21

This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.


Patent
ARIAD Pharmaceuticals Inc. | Date: 2016-02-16

The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula I: wherein the variables are as defined herein.

Loading ARIAD Pharmaceuticals Inc. collaborators
Loading ARIAD Pharmaceuticals Inc. collaborators